[A20-113] Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Last updated 20.09.2021
Project no.:
A20-113
Commission:
Commission awarded on 30.11.2020 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Adults with symptomatic chronic heart failure with reduced ejection fraction
Hint of non-quantifiable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-03-01.
Federal Joint Committee (G-BA)
2021.05.20 A G-BA decision was published.